LabConnect to Showcase Innovative Ambient Sample Shipping System at DIA
Logistics can be one of the most complex aspects of successful clinical trials because samples shipped from study sites for testing at a central laboratory may come with very limited temperature range requirements.
“Logistics can account for as much as 40 percent of the total cost of a clinical trial, and large bulky shippers are a huge irritant to sites,” said LabConnect President and CEO Eric Hayashi. “Validated cold-chain solutions are expensive, so controlled ambient shipping solutions like the Snuggy Clinical Kit are becoming increasingly important in PBMC and other analyses where high cellular viability and yields are critical.”
The Snuggy Clinical Kit was initially custom-designed for a two-year clinical study of progressive multiple sclerosis.
“We set out to develop a compact shipping system to save sites space and save our clients money while maintaining the test tubes within a very limited target temperature range,” Hayashi said. In multiple tests exposing the Snuggy Clinical Kit to extreme heat and cold, temperature variability remained well within the client’s requirements.
“When our
In addition to custom kit-building, LabConnect’s services to the biopharmaceutical industry include routine and specialized testing, biostorage and scientific operations support services utilizing advanced data management and reporting systems. To see a demonstration of the Snuggy Clinical Kit, an ambient specimen shipping system, visit LabConnect in booth #616 at DIA.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025